FDA postpones approval of afrezza
-
Last Update: 2014-04-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Ding Xiangyuan 2014-04-09 mannkind said that the US FDA extended the review of its inhaled insulin treatment drug afrezza for three months The news came a week after an FDA advisory panel recommended approval of the drug, but said longer-term studies were needed to assess the risk of lung cancer and other potential side effects On April 7, Mann kind said that the new due date for review is July 15, when the FDA will release complete review information for the submitted materials Analysts predict that FDA is delaying its decision in view of the safety and effectiveness of afrezza Afrezza consists of a whistle sized inhaler designed to deliver insulin powder to the lungs, making insulin easier to use than traditional insulin injections If approved, afrezza will be the first inhaled insulin treatment drug available in the United States since 2006 Source address: http://
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
